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S U M M A R Y
Background: Pneumococcal infections remain a major medical problem associated with high morbidity
and mortality. Moreover, the resistance of Streptococcus pneumoniae to conventional antibiotics is
constantly growing. The implementation of pneumococcal conjugate vaccines (PCVs) in the last decade
has dramatically reduced the incidence of the vaccine type-associated invasive pneumococcal
diseases in many countries. However, information on the seroepidemiology of S. pneumoniae in Russia
is limited.
Methods: We report the results of serotyping and antibiotic susceptibility testing performed on 863 non-
invasive pneumococcal isolates collected prospectively in 2009–2013 from children (median age 3.5
years) who sought medical care at ﬁve pediatric hospitals in Moscow. The isolates were recovered from
the nasopharynx (71.2%), middle ear ﬂuid (14.3%), and lower respiratory tract specimens (13.6%).
Results: In total, we identiﬁed 45 different serotypes. The six leading serotypes (prevalence >5%)
included 19F (21.7%), 6B (12.8%), 23F (10.1%), 14 (9.0%), 6A (8.4%), and 3 (7.5%). Serotype 19A isolates had
a prevalence of 2.3%. The proportion of PCV-13 serotypes was 78%; the coverage by PCV-7 was 58.2% and
was similar to that of PCV-10 (59.8%). The rate of multidrug-resistant pneumococci (i.e., resistant to 3
antimicrobials) was 22%. The majority of the multidrug-resistant isolates were serotype 6B, 14, 19A, and
19F. Penicillin non-susceptibility was displayed by 28% of the isolates. The resistance rate to
erythromycin was 26%. Among the examined erythromycin-resistant strains, 54% had the erm(B) gene
and 13% had the mef gene as a single resistance determinant, whereas both determinants were found in
31% of these strains.
Conclusions: Our data predict a good coverage of the circulating S. pneumoniae by the PCVs and could be
useful for evaluating the serotype distribution in support of the introduction of PCV in Russia. In addition,
the antimicrobial resistance rate of S. pneumoniae in Russia is substantial, and the emergence of
pneumococcal strains with a dual macrolide resistance mechanism is alarming.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Streptococcus pneumoniae (pneumococcus) is a common
bacterial pathogen responsible for various infections, especially
in children. The severity of pneumococcal illness varies from self-* Corresponding author. Tel.: +7 499 134 02 18.
E-mail address: mayansky@nczd.ru (N. Mayanskiy).
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http://dx.doi.org/10.1016/j.ijid.2013.11.005limiting mucosal infections to life-threatening invasive diseases
like bacteremia and meningitis. S. pneumoniae is the leading cause
of pediatric community-acquired pneumonia and acute otitis
media (AOM), which have a substantial burden on healthcare
resources worldwide.1–4 Pneumococcal infections contribute to a
large number of medical care visits and antibiotic prescriptions in
children. This coincides with the growing antibacterial resistance
of S. pneumoniae to a wide range of antibiotics that are used to treat
pneumococcal infections.5–7
The real burden of pediatric pneumococcal infections in the
Russian Federation is difﬁcult to estimate precisely because the
surveillance system is underdeveloped. A low rate of blood andociety for Infectious Diseases. Open access under CC BY-NC-SA license.
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practice of parenteral antibiotic administration in children
suspected to have bacteremia or meningitis before any laboratory
investigations, preclude the assessment of the true incidence of
invasive pneumococcal disease (IPD) in these patients. In addition,
only a few laboratories in the country are able to isolate, identify,
and serotype S. pneumoniae reliably. Thus, ﬁgures on the incidence
of IPD in the Russian Federation are mainly based on expert
evaluations. These data estimate the following incidence of IPD per
100 000 children under 6 years of age per year: pneumococcal
meningitis, 0.22–0.53; pneumococcal bacteremia, 58.5–130;
pneumococcal community-acquired pneumonia, 490–1300.1,8–10
In addition, the incidence of severe hospitalized pneumococcal
AOM has been assessed as being 97.4–122.1 per 100 000.8
Pneumococcal capsular polysaccharide represents the principal
virulence factor that protects the bacteria from phagocytosis and
generates the speciﬁc antibody immune response. More than 90
variants of capsular polysaccharide, i.e. pneumococcal serotypes,
have been described so far. Not all serotypes are equally
pathogenic, and the majority of pneumococcal infection is
associated with a limited number of serotypes.11 A subset of
capsular polysaccharides from clinically important serotypes is
included in the pneumococcal polysaccharide conjugate
vaccines (PCV). The introduction of PCVs into national immuni-
zation programs has been shown to substantially decrease the
incidence of IPD caused by vaccine-type pneumococci in many
countries.2,12–16
Three PCVs (7-, 10-, and 13-valent) are licensed in the Russian
Federation, but none has yet been implemented in the national
immunization program. To estimate the prophylactic potential of
the PCVs on pneumococcal infections, it is important to know how
close they match the set of circulating serotypes. The actual local
data on pneumococcal serotypes are limited and fragmented, and
only a few reports from Russia have been published in the
international literature in the last decade.17–19 In the present
article, we report serotyping and antibiotic susceptibility testing
data for a large collection of S. pneumoniae clinical non-invasive
isolates obtained prospectively in a number of pediatric hospitals
in Moscow. The vast majority of isolates were recovered from non-
sterile respiratory specimens and middle ear ﬂuid (MEF) from
children who sought medical care suffering primarily from acute
febrile respiratory infections and AOM.
2. Materials and methods
This prospective study included all isolates of S. pneumoniae
that were recovered from specimens collected at ﬁve pediatric
hospitals located in Moscow during March 2009 to April 2013. The
pneumococci were isolated from various biological materials
collected from patients (median age 3.5 years, interquartile range
0.08–6.0 years) with fever and symptoms of an acute respiratory
infection presumably of bacterial etiology, with AOM, and with
chronic lung disease.
S. pneumoniae was isolated from several specimen types,
including nasopharyngeal swabs, lower respiratory tract speci-
mens (sputum, tracheal, or bronchial aspirates), MEF obtained
from children with AOM by tympanocentesis or by swabbing the
ear discharge in the case of spontaneous draining, and some others.
Biological material was collected using an eSWAB kit (Copan, Italy).
Signed informed consent was obtained from the parents or legal
representatives of enrolled children before sampling.
All specimens were delivered to the laboratory of the Scientiﬁc
Center for Children’s Health (Moscow) and processed there within
24 h after sampling. The specimens were plated on blood agar
medium with 5% sheep blood and 2% horse serum and incubated at
37 8C with 5% CO2 for 24–48 h. S. pneumoniae was identiﬁed byoptochin test and latex agglutination with the Slidex pneumo-kit
(bioMe´rieux, France). Serotyping was performed by pool antisera
for latex agglutination and factor/type antisera in the Quellung
reaction using Staten Serum Institut products (SSI, Copenhagen,
Denmark). Isolates that agglutinated none of the pool sera (A to I
and P to T) were considered non-typeable.
Antibiotic susceptibility testing was done using the disk
diffusion method with disks from Bio-Rad (USA). Oxacillin-
resistant isolates were further tested for penicillin susceptibility
by E-test strips (Oxoid, UK). The penicillin minimum inhibitory
concentration (MIC) category interpretations were based on
updated standards (European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) 2012). Intermediate and resistant
isolates were collectively grouped as non-susceptible. A PCR was
used to detect the erm(B) and mef determinants of macrolide
resistance, as described previously.19
The statistical analysis was performed using IBM SPSS Statistics
for Windows, version 20.0 (IBM Corp., Armonk, NY, USA).
Contingency table analysis for comparing serotype distributions
was done by Chi-square or Fisher’s exact test, where appropriate.
Proportions of serotypes were compared by means of the
Z-criterion. The tests were considered statistically signiﬁcant at
p < 0.05.
3. Results
In total, 863 pneumococcal isolates were collected. The
majority of strains were obtained from nasopharyngeal swabs (n
= 617, 71.2%). One hundred eighteen isolates (13.6%) were
recovered from sputum and tracheal/bronchial aspirates (lower
respiratory tract specimens), and MEF provided 124 (14.3%)
isolates. In addition, four strains were isolated from other loci
(three from the vagina and one from the eye).
3.1. Serotype distribution
Serotyping was performed for 835 isolates; 10 (1.2%) isolates
were not preserved for typing and 18 (2.1%) strains were non-
typeable. Thus, the serotype was determined in 835 (96.8%)
pneumococcal isolates.
In total, 45 different serotypes were identiﬁed. Six major
serotypes accounted for 69.5% of the distribution and included
serotype 19F (21.7%), 6B (12.8%), 23F (10.1%), 14 (9.0%), 6A (8.4%),
and 3 (7.5%) isolates (Table 1).
Among the nasopharyngeal specimens, 44 different serotypes
were recovered, whereas only 18 different serotypes were isolated
from the MEF specimens. Serotype prevalence in nasopharyngeal,
lower respiratory tract, and MEF specimens compared by the Chi-
square test was different (Chi-square = 118, p = 0.018), however a
paired statistical analysis showed that the proportion of serotypes
varied signiﬁcantly only between nasopharyngeal and MEF
specimens (Chi-square = 64, p = 0.015). Serotype 3 (12.3% vs.
6.8%, Z = 2.13, p = 0.033) and 19A (6.6% vs. 1.6%, Z = 3.42, p = 0.001)
strains were more prevalent among MEF isolates than among the
other specimen types. In contrast, no serotype 11A isolates were
recovered from MEF, and the proportion of this serotype was
signiﬁcantly higher in the nasopharyngeal and lower respiratory
tract specimens (0% vs. 3.5%, Z = 2.11, p = 0.039). The prevalence
of all remaining serotypes was not statistically different between
the specimen sources.
The four S. pneumoniae strains recovered from the other loci had
serotypes 11A, 19F, 23F (vaginal isolates) and 6A (a conjunctival
isolate).
Considering marginal differences in the serotype distribution,
the pneumococci from all sources were collectively designated as
‘non-invasive isolates’ for further analysis.
Table 1
Distribution of Streptococcus pneumoniae serotypes in relation to PCV coverage
Serotype Number % of all typed Cumulative %
PCV-7
4 6 0.7
6B 107 12.8
9V 13 1.6
14 75 9.0
18C 20 2.4
19F 181 21.7
23F 84 10.1
Total 486 58.2 58.2
Additional in PCV-13
1 3 0.4
3 63 7.5
5 0 0.0
6A 70 8.4
7F 10 1.2
19A 19 2.3
Total 165 19.8 78.0
Non-PCV
9N 12 1.4
10A 9 1.1
11A 26 3.1
15B 29 3.5
15C 13 1.6
23A 17 2.0
37 11 1.3
Othera 67 8.0
Total 184 22.0 100.0
All typed 835 96.8
Non-typeable 18 2.1
Not typed 10 1.2
Overall 863 100.0
PCV, polysaccharide conjugate vaccine.
a Other are serotypes with a prevalence <1% in the distribution. These were 26
non-PCV serotypes (n): 7C (1), 8 (4), 9A (1), 10B (1), 11D (1), 12B (1), 12F (2), 13 (2),
15A (3), 16F (5), 17F (6), 18A (1), 20 (1), 21 (1), 22F (3), 23B (3), 28A (2), 28F (1), 33F
(3), 34 (6), 35B (2), 35C (5), 35F (7), 38 (1), 39 (2), 42 (2).
Figure 1. Serotype distribution of Streptococcus pneumoniae isolates in different age gro
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variation (Figure 1). Serotype proportions in three age groups
(24 months, 25–48 months, and >48 months) were signiﬁcantly
different (Chi-square = 63, p = 0.002), but these differences were
related to a limited number of serotypes. The prevalence of
serotype 19F isolates was higher among children aged 48 months
than in the older children (25% vs. 16%, Z = 3.27, p = 0.001), whereas
serotype 3 (5% vs. 12%, Z = 3.44, p = 0.001) and 37 (0.2% vs. 3%, Z =
3.63, p < 0.001) isolates prevailed in children aged >48 months.
The proportion of the remaining major serotypes was similar in all
age groups with no statistically signiﬁcant differences (Figure 1). In
addition, pneumococci of rare serotypes with a prevalence <1% in
the overall distribution (the ‘Other’ category in Figure 1) collec-
tively had a higher rate in children aged >48 months than in
younger children (13% vs. 6%, Z = 3.47, p = 0.001).
3.2. Antibiotic susceptibility of S. pneumoniae
Susceptibility to antibiotics was examined in 835 (96.8%)
pneumococcal isolates (Table 2). The prevalence of resistant
strains was above 20% for all tested antimicrobials. The highest
resistance rate (57%) was observed for trimethoprim/sulfameth-
oxazole. About 30% of pneumococcal strains were resistant to
oxacillin. To elucidate the beta-lactam susceptibility pattern
further, penicillin susceptibility was analyzed in 189 out of 243
(78%) of the oxacillin-resistant isolates. Thirteen of 189 (7%)
penicillin-susceptible pneumococci had a MIC 0.06 mg/ml. The
remaining isolates (93%, 176/189) were not susceptible to
penicillin, having MICs >0.06 mg/ml. Among these isolates, the
proportion of strains with a penicillin MIC 2 mg/ml was 10% (18/
176). Thus, the rate of penicillin non-susceptibility was estimated
as 28%. Penicillin non-susceptibility was found predominantly in
serotype 14, 19A, 19F, and 23F isolates.
Resistance to erythromycin was found in 26% of pneumococcal
isolates. Examination of the molecular mechanisms underlying the
macrolide resistance was performed in 157 out of 218 (72%)ups. Included are 17 serotypes that had a prevalence 1% and collectively covered
–48 months, n = 280; >48 months, n = 321.
Table 2
Antibiotic resistance of S. pneumoniae isolates
Number of isolates tested for antibiotic resistance % of resistant isolates
Oxacillin Erythromycin Clindamycin TMP/SMX MDRb
All serotypes (n = 835) 29 26 20 57 22
Serotypea
3 (n = 60) 2 0 0 5 0
6A (n = 66) 23 18 5 75 8
6B (n = 105) 16 46 39 63 31
11A (n = 25) 0 0 0 16 0
14 (n = 75) 64 43 29 77 40
15B (n = 29) 14 0 0 79 0
18C (n = 19) 11 0 0 26 0
19A (n = 19) 90 58 32 79 63
19F (n = 177) 57 52 44 79 48
23A (n = 17) 0 6 0 35 0
23F (n = 80) 32 6 4 64 6
TMP/SMX, trimethoprim/sulfamethoxazole; MDR, multidrug-resistant.
a Included are 11 serotypes that had a prevalence 2% and represented 82.7% of the distribution.
b Multidrug-resistant isolates, i.e. resistant to three or four tested antimicrobials. Other serotypes that had MDR phenotypes included (n MDR/n total): 8 (1/4), 9N (2/12),
9 V (3/12), 15A (1/3), 35C (1/5).
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erm(B) and mef genes. As a single determinant of macrolide
resistance, 54% (85/157) of strains had the erm(B) gene and 13%
(20/157) had the mef gene. Both erm(B) and mef genes were found
in 31% (48/157) of the examined strains. Four erythromycin-
resistant strains had neither erm(B) nor mef genes.
A multidrug resistance phenotype (MDR; resistance to 3
classes of antibiotic) was found in 22% of the isolates. Notably,
antibiotic resistance was attributed to a limited number of the
pneumococcal serotypes. A high resistance rate was mainly found
in four serotypes: 6B, 14, 19A, and 19F (Table 2). Among these
serotypes, serotype 19A demonstrated the most resistant proﬁle,
with resistance rates varying from 90% (17/19) to oxacillin to 32%
(6/19) to clindamycin. The majority of the 19A pneumococci (63%,
12/19) had an MDR phenotype.
Serotype 3 largely preserved susceptibility to the tested
antibiotics. One oxacillin-resistant strain of this serotype had a
penicillin MIC <0.06 mg/ml, thus being penicillin-susceptible, and
only 5% (3/60) of strains were resistant to trimethoprim/
sulfamethoxazole. None of the serotype 3 isolates had an MDR
phenotype. The majority of the serotype 23F isolates were
susceptible to oxacillin, erythromycin, and clindamycin; the rate
of MDR phenotypes in the serotype 23F strains was 6% (5/80).
In addition, several rare serotypes had an MDR phenotype.
These included serotype 8 (one out of four isolates were MDR
strains), 9N (2/12), 9 V (3/12), 15A (1/3), and 35C (1/5). No other
serotypes were MDR.
3.3. PCV coverage
The overall prevalence of PCV-7 serotypes in the recovered
isolates was 58.2% (Table 1). Six additional serotypes included in
PCV-13 increased coverage by 20% up to 78%, mainly due to
serotypes 3, 6A, and 19A. No serotype 5 strain was identiﬁed in the
examined collection. In comparison to PCV-7, the 10-valent PCV
having three more serotypes (1, 5, and 7F) covered an additional
1.6% of the distribution. Importantly, PCV coverage was even
higher in children at the age of 24 months, who are at the highest
risk of developing IPD. The coverage rate in this age group was
62.8% for PCV-7, 64.5% for PCV-10, and 81.2% for PCV-13.
Non-PCV serotypes had a prevalence of 22%. Among these,
isolates from serogroup 15 accounted for 5.1% and serotype 11A for
3.1% of the overall distribution (Table 1). The remaining rare 26
non-PCV serotypes (proportion of each one <1% in the total
distribution; listed in the footnotes to Table 1) collectively
comprised 8%.The PCVs covered the majority of serotypes that had MDR
phenotypes (PCV-7 and PCV-10, 87.7%; PCV-13, 97.2%). In addition,
most of the penicillin-non-susceptible isolates had PCV-related
serotypes.
4. Discussion
The results of this study describe the serotype assortment and
antibiotic susceptibility of non-invasive S. pneumoniae isolated
from pediatric patients. Serotype 3, 6A, 6B, 14, 19F, and 23F isolates
were predominant, covering two-thirds of the distribution, with
serotype 19F having the largest proportion at >20%. Comparison of
the serotype distributions obtained from different specimen
sources showed statistically signiﬁcant differences in the preva-
lence of several serotypes between the respiratory specimens and
MEF. Serotype diversity was much higher in the respiratory
samples than in MEF (44 vs. 18 different serotypes). The recovery
of serotype 3 and 19A isolates from MEF was higher than from
other specimen sources. In contrast, serotype 11A was found
exclusively in the respiratory specimens and not in MEF. This
serotype is one of the typical carriage serotypes that are rarely
associated with pneumococcal disease,11,15,20 although some
carriage serotypes may have the potential to cause IPD, which
has become apparent under PCV pressure. For instance in the USA,
the recovery of serotype 22F, 23A, and 35B isolates in IPD has
increased substantially since the introduction of PCV-7.15
The PCVs have been shown to exert a profound inﬂuence on the
epidemiology of S. pneumoniae serotypes. In countries where
universal PCV-7 vaccination has been introduced, vaccine-type
pneumococci have virtually disappeared.15,20 Considering these
data, we compared our current ﬁndings with pre-PCV reports
because pneumococcal vaccination has not yet been introduced
into the national immunization program in Russia. Despite the
above indicated relative differences, the composition of the major
serotypes in all specimen sources was similar. Therefore for
comparison purposes, we regarded isolates recovered from the
different specimen sources as one distribution of non-invasive
pneumococcal strains. Our results indicated that the assortment
and recovery rate of the major serotypes in the present study were
similar to those described in the pre-PCV era worldwide, when the
leading non-invasive isolates were represented by S. pneumoniae
from serogroups 3, 6, 14, 19, and 23.2,12–16 These are the typical
pediatric pneumococci that accounted for most IPD in children and
had high carriage rates before the implementation of the PCV.11,21
The antibiotic resistance rate in the isolated pneumococci was
substantial. Given that 93% of oxacillin-resistant strains were
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of penicillin-non-susceptibility could be estimated as 28%.
Macrolide resistance was above 25%, and 22% of isolates had an
MDR phenotype. In earlier studies performed in Russia on
nasopharyngeal pneumococcal isolates collected in the late 1990s
and in 2001–2002, the prevalence of non-susceptible strains was
much lower.17,18 The rate of the penicillin-non-susceptible
S. pneumoniae was below 10%, the proportion of erythromycin-
resistant strains was around 5%, and only2% MDR pneumococci were
reported. Resistance to trimethoprim/sulfamethoxazole was similar
to what was found in the present study (53–65%). Our ﬁndings
indicatethatinthelastdecadeasigniﬁcant increaseintheprevalence
ofresistantS.pneumoniae has occurred.Thisresultcoincideswiththe
global trend of a progressive increase in the prevalence of resistant
pneumococci when penicillin-non-susceptibility has increased from
negligible to a rate of 25–50% in many geographic locations.5–7
The same is true for macrolides, for which resistance rates in
Russia have increased from 5% in 2001–2002 to 26% today.17–19
Our study demonstrated that the predominant mechanism of
macrolide resistance was the target site modiﬁcation mediated by
the erm(B)-encoded methylase found in 54% of the erythromycin-
resistant isolates as a single determinant and in 31% in association
with the mef-related efﬂux pump. In addition, in 13% of the
erythromycin-resistant isolates, only mef was identiﬁed. The rates
of erm(B), mef, and their combination were similar to those
reported for 2004–2005 isolates from Russia.19 In contrast, in a
collection from the late 1990s to 2002, no pneumococci carrying
both determinants were reported.18 Thus, in the last decade,
macrolide resistance of S. pneumoniae in Russia has increased
signiﬁcantly and strains combining erm(B) and mef determinants
have emerged. The emergence of pneumococci with a dual
resistance mechanism is alarming because this phenotype has
been related to genetic elements from the MDR pneumococcal
clonal complexes with the highest resistance.22
In our study, PCV serotypes predominated among recovered
pneumococcal isolates, with PCV-13 having the highest coverage,
close to 80%. Moreover, the majority of resistant S. pneumoniae,
including bacteria with an MDR phenotype, were vaccine-type
pneumococci. Although we examined non-invasive pneumococci,
these data predict an excellent protective potential of the available
PCVs against IPD in Russia because most pediatric pneumococcal
diseases in the pre-PCV era have been associated with the
serotypes that predominated in the presented collection (see
above). In addition, the PCVs may contribute to a reduction in the
circulation of the resistant pneumococcal clones, which often have
vaccine-related serotypes.
In conclusion, to our knowledge this is the largest study
reporting the distribution of non-invasive pneumococcal serotypes
from the Russian Federation. These data may be used as a starting
point to monitor and evaluate the future impact of the PCVs on the
seroepidemiology and antimicrobial resistance of S. pneumoniae in
the country after the implementation of PCV in the national
immunization program.
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